Generation and validation of a human iPSC-derived TDP-43 knockout model for ALS disease modeling.

Problem Statement

Amyotrophic lateral sclerosis (ALS) is characterized by the nuclear depletion and cytoplasmic aggregation of the RNA-binding protein TDP-43, a pathological hallmark found in approximately 97% of ALS cases. This dysfunction leads to the disruption of RNA processing, specifically through the aberrant inclusion of cryptic exons. However, existing cellular models for studying this mechanism suffer from significant limitations:

• Partial knockdown: Fails to fully recapitulate the complete loss of function.
• TARDBP mutations: May not represent the most common pathological mechanism (loss of function).
• Pharmacological stress: Induces non-physiological stress responses that complicate the interpretation of TDP-43-specific effects.

There is a critical need for a genetically defined model that completely eliminates TDP-43 to accurately study its role in neurodegeneration and screen for therapeutic interventions.

Methodology

To address these gaps, the researchers employed a multi-step approach combining genome editing, differentiation, and biosensor integration:

1. CRISPR-Cas9 Genome Editing: They generated homozygous TARDBP-knockout (KO) human induced pluripotent stem cell (iPSC) lines.
2. Differentiation: These iPSC lines were differentiated into spinal motor neurons (MNs) to create a disease-relevant cellular context.
3. Biosensor Integration: The team integrated the CUTS splice biosensor into the model. This reporter system is designed to detect cryptic exon inclusion by inducing GFP expression when splicing errors occur.
4. Pharmacological Validation: The model was used to test cardiac glycosides (digoxin and ouabain) as potential modulators of TDP-43 pathology, specifically in the context of bortezomib-induced stress.

Key Results

• Differentiation Efficiency: The TARDBP-KO iPSCs exhibited a severe phenotype, showing approximately 16-fold lower differentiation efficiency into motor neurons compared to isogenic control lines. Despite this hurdle, the resulting MNs retained expression of standard neuronal markers.
• Molecular Consequences: The loss of TDP-43 triggered widespread molecular defects, including:
  • Extensive cryptic exon inclusion across the transcriptome.
  • Significant depletion of key downstream targets, specifically STMN2, UNC13A, and G3BP1, which are known to be critical for neuronal health and ALS pathology.
• Reporter Readout: The integration of the CUTS biosensor proved highly effective, yielding up to a 4.5-fold induction of cryptic GFP in the knockout MNs. This provided a robust, quantitative, reporter-based readout for TDP-43 dysfunction.
• Therapeutic Modulation: The study successfully validated that cardiac glycosides, specifically digoxin and ouabain, could modulate TDP-43 pathology induced by bortezomib, demonstrating the model's utility in drug screening.

Key Contributions

• First Homozygous KO Model: The creation of a genetically defined, homozygous TARDBP-knockout human iPSC-derived motor neuron model, overcoming the limitations of partial knockdown or mutation-based models.
• Biosensor Platform: The successful adaptation of the CUTS splice biosensor in human MNs, offering a scalable and sensitive method to quantify cryptic splicing events without relying solely on complex sequencing.
• Mechanistic Insight: Direct demonstration of the causal link between complete TDP-43 loss and the depletion of STMN2/UNC13A in a human neuronal context.

Significance

This study establishes a powerful new platform for the mechanistic and therapeutic interrogation of TDP-43-driven neurodegeneration. By providing a model that faithfully recapitulates the complete loss of TDP-43 function and includes a high-throughput reporter system, the authors enable:

1. Deeper Understanding: A clearer dissection of how TDP-43 loss specifically drives RNA processing errors and neuronal death.
2. Drug Discovery: A robust screening environment for identifying compounds that can rescue cryptic splicing or restore the levels of critical targets like STMN2.
3. Therapeutic Validation: The immediate validation of cardiac glycosides suggests a potential repurposing strategy for ALS treatment, highlighting the model's translational potential.